Abstract:A low-energy electronic brachytherapy source (EBS), the model S700 Axxent x-ray device developed by Xoft Inc., has been used in high dose rate (HDR) intracavitary accelerated partial breast irradiation (APBI) as an alternative to an Ir-192 source. The prescription dose and delivery schema of the electronic brachytherapy APBI plan are the same as the Ir-192 plan. However, due to its lower mean energy than the Ir-192 source, an EBS plan has dosimetric and biological features different from an Ir-192 source plan. Current brachytherapy treatment planning methods may have large errors in treatment outcome prediction for an EBS plan. Two main factors contribute to the errors: the dosimetric influence of tissue heterogeneities and the enhancement of relative biological effectiveness (RBE) of electronic brachytherapy. This study quantified the effects of these two factors and revisited the plan quality of electronic brachytherapy APBI. The influence of tissue heterogeneities is studied by a Monte Carlo method and heterogeneous 'virtual patient' phantoms created from CT images and structure contours; the effect of RBE enhancement in the treatment outcome was estimated by biologically effective dose (BED) distribution. Ten electronic brachytherapy APBI cases were studied. The results showed that, for electronic brachytherapy cases, tissue heterogeneities and patient boundary effect decreased dose to the target and skin but increased dose to the bones. On average, the target dose coverage PTV V(100) reduced from 95.0% in water phantoms (planned) to only 66.7% in virtual patient phantoms (actual). The actual maximum dose to the ribs is 3.3 times higher than the planned dose; the actual mean dose to the ipsilateral breast and maximum dose to the skin were reduced by 22% and 17%, respectively. Combining the effect of tissue heterogeneities and RBE enhancement, BED coverage of the target was 89.9% in virtual patient phantoms with RBE enhancement (actual BED) as compared to 95.2% in water phantoms without RBE enhancement (planned BED). About 10% increase in the source output is required to raise BED PTV V(100) to 95%. As a conclusion, the composite effect of dose reduction in the target due to heterogeneities and RBE enhancement results in a net effect of 5.3% target BED coverage loss for electronic brachytherapy. Therefore, it is suggested that about 10% increase in the source output may be necessary to achieve sufficient target coverage higher than 95%.

Key comparison BIPM.RI(I)-K8 of high dose-rate 192 Ir brachytherapy standards for reference air kerma rate of the PTB and the BIPM

Key comparison BIPM.RI(I)-K8 of high dose-rate 192 Ir brachytherapy standards for reference air kerma rate of the LNE-LNHB and the BIPM

Key comparison BIPM.RI(I)-K2 of the air-kerma standards of the PTB, Germany, and the BIPM in low-energy x-rays

Key comparison BIPM.RI(I)-K3 of the air-kerma standards of the PTB, Germany, and the BIPM in medium-energy x-rays

Key comparison BIPM.RI(I)-K5 of the air-kerma standards of the BEV, Austria and the BIPM in 137 Cs gamma radiation

Key comparison BIPM.RI(I)-K5 of the air-kerma standards of the CIEMAT, Spain and the BIPM in 137 Cs gamma radiation

Key comparison BIPM.RI(I)-K7 of the air-kerma standards of the BFKH, Hungary, and the BIPM in mammography x-rays

Comparison of the standards for absorbed dose to water of the IAEA and the KRISS, Korea in accelerator photon beams

Update of the BIPM comparison BIPM.RI(II)-K1.Tb-161 of activity measurements of the radionuclide 161 Tb to include the 2022 result of the NPL (United Kingdom)

Update of the BIPM comparison BIPM.RI(II)-K1.Cs-137 of activity measurements of the radionuclide 137 Cs to include the 2014 result of the NRC (Canada) and the 2018 result of the TENMAK-NÜKEN (Türkiye)

Update of the BIPM comparison BIPM.RI(II)-K1.Co-57 of activity measurements of the radionuclide 57 Co to include the 2023 result of the BEV (Austria)

Beta Depth Dose Curves at STUK and PTB: measurements and simulations

International comparison of measurements of neutron source emission rate (2016-2021) - CCRI(III)-K9.Cf.2016

Bilateral Comparison of 1.018 V and 10 V Standards Between the KRISS (republic of Korea) and the BIPM, February 2008 (part of the Ongoing BIPM Key Comparison BIPM.EM-K11.a and B)

Update of the BIPM comparison BIPM.RI(II)-K1.Cr-51 of activity measurements of the radionuclide 51 Cr to include the 2012 result of the KRISS (Rep. of Korea), the 2022 result of the POLATOM (Poland), and to link the 2022 EURAMET.RI(II)-K2.Cr-51 comparison

Update of the BIPM comparison BIPM.RI(II)-K1.Ge-68 of activity measurements of the radionuclide 68 Ge to include the 2021 result of the NIM (China)

Effective Dose for Patients Undergoing Coronary and Femoral Intravascular Radiotherapy Involving an HDR 192ir Source.

Experimental comparison of cylindrical and plane parallel ionization chambers for reference dosimetry in continuous and pulsed scanned proton beams

Applications of Tissue Heterogeneity Corrections and Biologically Effective Dose Volume Histograms in Assessing the Doses for Accelerated Partial Breast Irradiation Using an Electronic Brachytherapy Source

Bilateral comparison of 1.018 V and 10 V standards between INRIM (Italy) and the BIPM, November to December 2023 (part of the ongoing BIPM key comparison BIPM.EM-K11.a and b)

Quality assurance measurements for high-dose-rate brachytherapy without film